智盟生物宣布首个人体首期受试者给药--CB06临床试验

StephenW

智盟生物宣布首个人体首期受试者给药--CB06临床试验

     美通社 17 小时前

上海，2022 年 3 月 31 日 /美通社/ -- 上海智盟生物制药股份有限公司（简称“智盟”），一家专注于开发治疗慢性乙型肝炎和中枢神经系统疾病的创新药物的创新驱动型生物制药公司，宣布 为其新型 TLR8 激动剂 (CB06) 的美国 I 期研究的第一位参与者给药，该药物正在开发用于治疗慢性乙型肝炎病毒感染。

Zhimeng Biopharma Announces Dosing of First Subject in First-in-Human Phase -- Clinical Trial of CB06

    PR Newswire 17 hrs ago

SHANGHAI, March 31, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng"), an innovation-driven biopharmaceutical company focused on the development of innovative drugs for the treatment of chronic hepatitis B and central nervous system diseases, announced dosing of the first participant in the US Phase I study of its novel TLR8 agonist (CB06), which is being developed for the treatment of chronic hepatitis B virus infection.